Nodular sclerosing Hodgkin disease: New grading predicts prognosis in intermediate and advanced stages

Blood

Volumn 101, Issue 10, 2003, Pages 4063-4069

  Von Wasielewski, Sabine ^b   Franklin, Jeremy ^b   Fischer, Robert ^b   Hübner, Klaus ^b   Hansmann, Martin L ^b   Diehl, Volker ^b   Georgii, Axel ^b   Von Wasielewski, Reinhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; EOSINOPHILIA; HISTOLOGY; HODGKIN DISEASE; HUMAN; LABORATORY TEST; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MORPHOLOGICAL TRAIT; PRIORITY JOURNAL; PROGNOSIS; REED STERNBERG CELL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; CANCER STAGING; CLASSIFICATION; FEMALE; FOLLOW UP; IMMUNOLOGY; LYMPH NODE; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SCLEROSIS; SURVIVAL; TIME;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LYMPH NODES; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SCLEROSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0038603141     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1548     Document Type: Article

References (39)

1. Keller AR, Kaplan HS, Lukes RJ, Rappaport H. The correlation of histopathology with other prognostic indicators in Hodgkin's disease. Cancer. 1968;22:487-499.
2. Kadin ME, Glatstein E, Dorfman RE. Clinicalpathologic studies of 117 untreated patients subjected to laparotomy for the staging of Hodgkin's disease. Cancer. 1971;27:1277-1294.
3. Kirschner RH, Abt AB, O'Connell MJ, Sklansky BD, Greene WH, Wiernik PH. Vascular invasion and hematogenous dissemination of Hodgkin's disease. Cancer. 1974;34:1159-1162.
4. Colby TV, Hoppe RT, Warnke RA. Hodgkin's disease: a clinicopathologic study of 659 cases. Cancer. 1982;49:1848-1858.
5. Jelliffe AM, Hudson GV. The evolution of the British National Lymphoma Investigation (report no. 5). Clin Radiol. 1981;32:483-490.
6. Bergsagel DE, Alison RE, Bean HA, et al. Results of treating Hodgkin's disease without a policy of laparotomy staging. Cancer Treat Rep. 1982;66:717-731.
7. Cross RM. A clinicopathological study of nodular sclerosing Hodgkin's disease. J Clin Pathol. 1968;21:303-310.
8. MacLennan KA, Bennett MH, Tu A, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease: a study of 1659 patients. Cancer. 1989;64:1686-1693.
9. von Wasielewski R, Georgii A, Fischer R, et al. Clinical impact of grading the nodular sclerosing Hodgkin's disease under modern therapy of the German Hodgkin Study Group [abstract]. Leuk Lymphoma. 1998;29:O-3.
10. Georgii A, von Wasielewski R, MacLennan KA, et al. Nodular sclerosing Hodgkin shows significant differences in clinical course when graded by Histopathology [abstract]. Mod Pathol. 1998;11:129A.
11. Haybittle JL, Hayhoe FG, Easterling MJ, et al. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet. 1985;1:967-972.
12. Adamkov M, Plank L. Prognosticky relevantra histopatologicka subtypizacia nodularno-sklerotickeho typu Hodgkinovej Choroby [Prognostic relevance of histopathologic subtyping of nodular-sclerotic types of Hodgkin's disease]. Bratisl Lek Listy. 1990;91:433-436.
13. Wijlhuizen TJ, Vrints LW, Jairam R, et al. Grades of nodular sclerosis (NSI-NSII) in Hodgkin's disease: are they of independent prognostic value? Cancer. 1989;63:1150-1153.
14. Ferry JA, Linggood RM, Convery KM, Efird JT, Eliseo R, Harris NL. Hodgkin disease, nodular sclerosis type: implications of histologic subclassification. Cancer. 1993;71:457-463.
15. d'Amore ES, Lee CK, Aeppli DM, Levitt SH, Frizzera G. Lack of prognostic value of histopathologic parameters in Hodgkin's disease, nodular sclerosis type: a study of 123 patients with limited stage disease who had undergone laparotomy and were treated with radiation therapy. Arch Pathol Lab Med. 1992;116:856-861.
16. Masih AS, Weisenburger DD, Vose JM, Bast MA, Armitage JO. Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin's disease. Cancer. 1992;69:228-232.
17. Hess JL, Bodis S, Pinkus G, Silver B, Mauch P. Histopathologic grading of nodular sclerosis Hodgkin's disease: lack of prognostic significance in 254 surgically staged patients. Cancer. 1994;74:708-714.
18. van Spronsen DJ, Vrints LW, Hofstra G, Crommelin MA, Coebergh JW, Breed WP. Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 1972-92. Br J Haematol. 1997;96:322-327.
19. von Wasielewski R, Seth S, Franklin J, et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood. 2000;95:1207-1213.
20. Duehmke E, Franklin J, Pfreundschu M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol. 2001;19:2905-2914.
21. Sieber M, Tesch H, Pfistner B, et al. Rapidly alternating COPP/ABVD/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol. 2002;20:476-482.
22. Georgii A, Fischer R, Hübner K, Schwarze EW, Bernhards J. Classification of Hodgkin's disease biopsies by a panel of four histopathologists: report of 1,140 patients from the German National Trial. Leuk Lymphoma. 1993;9:365-370.
23. von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin's disease: clinical impact of the immunophenotype. Am J Pathol. 1997;151:1123-1130.
24. Coppleson LW, Rappaport H, Strum SB, Rose J. Analysis of the Rye classification of Hodgkin's disease: the prognostic significance of cellular composition. J Natl Cancer Inst. 1973;51:379-390.
25. Patchefsky AS, Brodovsky H, Southard M, Menduke H, Gray S, Hoch WS. Hodgkin's disease: a clinical and pathologic study of 235 cases. Cancer. 1973;32:150-161.
26. Cionini L, Arganini L, Mungai V, Biti GP, Bondi R. Prognostic significance of histologic subdivision of Hodgkin's disease nodular sclerosis. Acta Radiol Oncol Radiat Phys Biol. 1978;17:65-73.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete investigations. J Am Stat Assoc. 1959;53:457-482.
28. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
29. Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for Advanced Hodgkin's disease. N Engl J Med. 1999;339:1506-1514.
30. Eghbali H, Mathoulin-Pelissier S, Picot V, et al. Secondary cancers after Hodgkin's disease, a continuous life-threatening side effect [abstract]. Leuk Lymphoma. 2001;42(suppl 2):P-200.
31. Josting A, Ansen S, May M, et al. Incidence, treatment and prognosis of secondary leukemia and secondary myelodysplastic syndrome in patients treated for Hodgkin's disease in the German Hodgkin Study Group (GHSG) [abstract]. Leuk Lymphoma. 2001;42(suppl 2):P-208.
32. Rüffer U, Flechtner H, Josting A, Sieber M, Diehl V. Fatigue in patients with Hodgkin's disease: a report from the German Hodgkin Study Group [abstract]. Leuk Lymphoma. 2001;42(suppl 2):P-215.
33. Ben-Arush MW, Solt I, Lightman A, Linn S, Kuten A. Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2000;17:239-245.
34. Carbone A. Histologic subclassification of nodular sclerosis Hodgkin's disease. Tumori. 1979;65:743-751.
35. Mann RB, Jaffe ES, Berard CW. Malignant lymphomas - a conceptual understanding of morphologic diversity. A review. Am J Pathol. 1979;94:105-191.
36. DeVita VTJ. The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky Memorial Lecture. Cancer. 1981;47:1-13.
37. DeVita VT, Hubbard SV. The curative potential of chemotherapy in the treatment of Hodgkin's disease and non-Hodgkin's lymphomas. In: Rosenberg SA, Kaplan HS, eds. Malignant Lymphomas Aetiology, Immunology, Pathology, Treatment. New York, NY: Academic Press; 1982:379-418.
38. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26:1063-1081.
39. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.